07/03/2020
Neuropsychological Sequelae of SARS-CoV-2 Infection
Andrew Levine, PhD, ABPP
The neuropsychological sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the associated syndrome, coronavirus disease 2019 (COVID-19) are uncertain. Thus far, neurologic-focused case studies suggest that a minority of COVID-19 cases have symptoms ranging in severity from very mild (e.g., headache and loss of smell/taste) to severe (e.g., encephalitis, large vessel stroke).
However, the meaning of these observations is unclear, as the studies thus far have not included control groups consisting of uninfected patients with similarly severe symptoms (respiratory or otherwise) or those who have undergone similar medical procedures (e.g., ventilation and sedation) for other conditions.
Additionally, there are large discrepancies in case series findings, likely due to differences in data collection methods, and it is often unclear whether the patients described were tested for other potentially neuroinvasive viruses that can lead to similar neurological conditions as those reported for COVID-19.
There have been no studies on the neuropsychological outcomes of individuals infected with SARS-CoV-2 or survivors of COVID-19. However, there is good reason to anticipate cognitive sequelae due to direct and indirect mechanisms.
Concerning direct mechanism, previously identified human coronaviruses (HCoV), including SARS-CoV-1 and MERS-CoV, are both neuroinvasive and neurovirulent. During the 2002-2003 SARS outbreak, a variety of neurological conditions appeared 3-4 weeks into the course of the illness in a small number of patients, including polyneuropathy, encephalitis, and aortic ischemic stroke. MERS-CoV has been associated with reports of psychosis and seizures, altered mental status, paralysis, ischemic stroke, Guillain-Barré syndrome, and neuropathy, all of which appeared several weeks after the primary respiratory symptoms.
Assuming SARS-CoV-2, like other HCoVs, can have a lasting presence in the central nervous system (CNS), its potential to provoke a chronic neuroinflammatory immune response should be considered as a potential cause of neuropsychological deficits. Such chronic inflammation in the brain could conceivably result in neuropsychological deficits in the long-term, similar to HIV. Furthermore, chronic CNS viral infection may be associated with increased risk of neurodegenerative illness, such as dementia, as indicated by studies of human herpes viruses, Influenza A, and other HCoVs.
Concerning indirect mechanisms, cerebral strokes have been observed with greater frequency in relatively young COVID-19 patients. Furthermore, COVID-19 patients who develop acute respiratory distress syndrome (ARDS) are at risk of lowered levels of oxygen reaching the brain. Many of those with ARDS are intubated and treated with mechanical ventilators, a procedure with substantial neurologic risks, likely due to loss of oxygen to the brain. In addition, the “cytokine storms” reported in severe COVID-19 cases can cause multiple organ damage, leading to liver, kidney, or heart dysfunction, all of which can have adverse effects of cognitive functioning.
This acute inflammatory state can also be the result of more direct i CNS damage. Finally, some have proposed that CNS-related autoimmune disorders could arise post-SARS-CoV-2 infection, as has been reported in SARS-CoV-1 and MERS-CoV infection.
The psychological impact of COVID-19 illness is also relevant. Considering the relatively high fatality rate among individuals who become infected with SARS-CoV-2, as well as the emotional and financial devastation caused by the pandemic, psychological disorders such as posttraumatic stress disorder and depression will also need to be considered as primary diagnoses and factors that could potentially contribute to neurocognitive impairment. Indeed, there are now several reports of lasting psychological trauma among COVID-19 survivors.
As suggested thus far, the direct and indirect causes for neuropsychological deficits in COVID-19 survivors are varied and multifactorial. Therefore, in order to characterize the long-term neuropsychological sequelae of SARS-CoV-2 infection and/or COVID-19, large cohort studies that include both infected (historically or actively) and never-infected individuals will be required.
Such studies should include resource-limited countries and, domestically, over-sampling (proportionally) of African Americans and Latinos due to the greater impact the virus is having on their communities. Such studies will allow for longitudinal characterization of cognitive functioning while considering comorbidities and other potential factors affecting such functioning.
Full article available at https://www.north-coast-neuropsych.com/resources
Image: Source: https://bit.ly/38mVEfh